Glaukos Takes Major Step with Epioxa™ FDA Application
Glaukos Corporation (NYSE: GKOS), a distinguished ophthalmic pharmaceutical and medical technology enterprise, has made significant strides by filing a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for Epioxa™, its state-of-the-art keratoconus therapy. This innovative treatment leverages advanced techniques to address a progressive corneal disease affecting numerous individuals worldwide.
Epioxa Therapy: A New Hope for Keratoconus Patients
Epioxa™ features the next-generation iLink therapy aimed at treating keratoconus without the invasive procedure of epithelial removal. Thomas Burns, the Chairman and CEO of Glaukos, emphasizes that this submission embodies a vital milestone for the company and brings hope to patients battling this debilitating condition. Keratoconus progresses typically during the adolescent years, leading to thinning cornea and potentially severe complications, including vision loss and the need for corneal transplant. The absence of invasive techniques with Epioxa™ stands as a testament to Glaukos’ commitment to patient comfort and recovery.
Significant Clinical Trials Supporting Epioxa
The NDA submitted is underpinned by two Phase 3 pivotal trials. Both studies not only achieved primary efficacy endpoints but also demonstrated excellent safety and tolerability profiles. This robust clinical data highlights Epioxa's promise in revolutionizing treatment protocols for keratoconus.
Understanding Keratoconus
Keratoconus is a condition that predominantly impacts individuals in their late teens to early twenties. Approximately 90% of diagnosed patients experience it bilaterally, and nearly 20% ultimately require corneal transplants. Current treatment options available, such as glasses or contact lenses, primarily manage symptoms and do not halt disease progression. In contrast, Glaukos’ pioneering iLink therapy has set a precedent as the first FDA-approved treatment aimed at slowing or halting such relentless progress.
The Innovation Behind Epioxa’s Formulation
Epioxa employs a novel formulation designed specifically to penetrate the epithelial layer of the cornea effectively. Coupled with a stronger UV-A irradiation technique and supplemental oxygen, the therapy represents a bold step in cross-linking methodologies. If the FDA approves Epioxa™, it could become the first non-invasive therapy of its kind, further enhancing treatment options available to keratoconus patients.
About Glaukos Corporation
Glaukos has consistently been at the forefront of developing innovative solutions to combat glaucoma, corneal disorders, and retinal diseases. The firm spearheaded Micro-Invasive Glaucoma Surgery (MIGS) as an alternative treatment method, launching its ground-breaking MIGS device in 2012. As part of its ongoing commitment to innovation, Glaukos initiated launch activities for iDose® TR—a unique intracameral pharmaceutical that offers extended glaucoma therapy. Their exhaustive research and development initiatives highlight a continued dedication to enhancing patient quality of life.
Frequently Asked Questions
What is Epioxa™?
Epioxa™ is Glaukos Corporation's next-generation therapy aimed at treating keratoconus, utilizing a non-invasive procedure and innovative formulation.
Why is the NDA submission for Epioxa significant?
The NDA submission marks a crucial step toward providing patients with an FDA-approved therapy that can significantly improve their treatment options without invasive methods.
How does Epioxa™ differ from existing treatments?
Epioxa™ differs by eliminating the need to remove the corneal epithelium, allowing for a gentler, more comfortable treatment process.
What is keratoconus and its implications?
Keratoconus is a progressive eye condition characterized by thinning of the cornea, potentially leading to severe vision loss and the necessity for corneal transplant.
What future developments can we expect from Glaukos?
Glaukos aims to advance its innovative therapies and technologies, continuing its mission to enhance patient outcomes in ophthalmic care.
